| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 147 |
| 1 | RIBAVIRIN | 76 |
| 2 | SOFOSBUVIR | 74 |
| 3 | PREDNISONE | 61 |
| 4 | ACETAMINOPHEN | 48 |
| 5 | METHOTREXATE SODIUM | 44 |
| 6 | METHYLPREDNISOLONE | 43 |
| 7 | METHOTREXATE | 42 |
| 8 | TACROLIMUS | 41 |
| 9 | CYCLOPHOSPHAMIDE | 39 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DEXTROSE AND SODIUM CHLORIDE | 1 | 0.0060 |
| 1 | SOFOSBUVIR | 74 | 0.0038 |
| 2 | NINTEDANIB ESYLATE | 1 | 0.0029 |
| 3 | CHLORAMBUCIL | 9 | 0.0023 |
| 4 | BUPRENORPHINE HCL | 2 | 0.0023 |
| 5 | SODIUM THIOSULFATE | 1 | 0.0018 |
| 6 | CAPSAICIN | 6 | 0.0018 |
| 7 | BUPRENORPHINE AND NALOXONE | 2 | 0.0016 |
| 8 | RITUXIMAB-ABBS | 8 | 0.0016 |
| 9 | PROPYLTHIOURACIL | 3 | 0.0014 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 159 |
| 1 | Corticosteroid [EPC] | 146 |
| 2 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 100 |
| 3 | Nucleoside Analog Antiviral [EPC] | 76 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 74 |
| 5 | Alkylating Drug [EPC] | 47 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 42 |
| 7 | Loop Diuretic [EPC] | 36 |
| 8 | Benzodiazepine [EPC] | 35 |
| 9 | Interferon alpha [EPC] | 32 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Opioid Antagonist [EPC] | 2 | 0.0021 |
| 1 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 100 | 0.0019 |
| 2 | Nucleoside Analog Antiviral [EPC] | 76 | 0.0009 |
| 3 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 4 | Sulfone [EPC] | 9 | 0.0008 |
| 5 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 6 | Hepatitis C Virus NS5A Inhibitor [EPC] | 31 | 0.0006 |
| 7 | Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC] | 1 | 0.0006 |
| 8 | Type I Interferon Receptor Antagonist [EPC] | 1 | 0.0005 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 159 | 0.0005 |